HIV-1整合酶天然多态性K156N与3'PPT突变在度鲁特韦单药治疗失败中的协同作用
本研究基于DOMONO随机临床试验中一例度鲁特韦单药治疗失败并出现3'PPT突变的参与者,发现基线HIV-1整合酶存在K156N天然多态性。通过计算机模拟和生化实验,评估K156N对整合酶功能及病毒学特征的影响,并分析其与3'PPT突变的相互作用。结果显示K156N改变病毒DNA结合,部分补偿3'PPT突变导致的感染性和复制能力缺陷,但不增加度鲁特韦耐药性。
要点
- K156N天然多态性可能 predispose 携带该变异的个体在DTG治疗失败时出现3'PPT突变。
- K156N不单独赋予度鲁特韦耐药性,也不增加3'PPT突变介导的低水平耐药。
- K156N可部分补偿3'PPT突变导致的感染性和复制能力缺陷,但最大感染性仍降低。
核心结论
- HIV-1整合酶天然变异K156N与3'PPT突变的出现存在直接功能关系,携带K156N的病毒可能在DTG治疗失败时易发展为3'PPT突变,但临床相关性尚待确立。
研究设计与样本
- 基于DOMONO随机临床试验中一例DTG单药治疗失败参与者的基线病毒序列分析,采用计算机模拟和重组蛋白生化实验,并测量携带K156N、3'PPT突变或两者病毒的感染性、复制能力和药物敏感性,并在细胞培养中评估病毒进化。
主要发现
- 结构模型显示K156N改变病毒DNA结合;K156N降低链转移活性(对LTR亲和力下降)但增加3'端加工。
- K156N病毒具有正常感染性,而3'PPT突变使感染性降低6倍并降低最大感染性;K156N部分补偿该缺陷,但最大感染性仍降低。
- K156N部分补偿3'PPT突变导致的复制能力缺陷;K156N单独不赋予度鲁特韦耐药性,也不增加3'PPT突变介导的2.5倍耐药。
- K156N单独促进与DOMONO中所见不同的3'PPT突变自发出现。
临床怎么用
- 对于携带HIV-1整合酶K156N天然多态性的个体,在DTG治疗失败时需警惕3'PPT突变的出现,但该关联的临床意义尚未确定。
局限性
- K156N与3'PPT突变关联的临床相关性尚未建立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mutations in the 3'-polypurine tract (3'PPT) of HIV-1 have been observed under pressure with two integrase strand transfer inhibitors, dolutegravir and cabotegravir. In the DOMONO randomized clinical trial, 3'PPT mutations emerged in a participant who experienced treatment failure under dolutegravir monotherapy. To understand the basis for this rare mutational pathway, we examined baseline viral sequences and identified the K156N natural polymorphism. Given the role of K156 in viral DNA binding, the potential relationship between K156N and 3'PPT mutations was further investigated. METHODS: We assessed the impact of K156N on integrase using in silico modelling and biochemical assays with recombinant proteins. Infectivity, replicative capacity, and drug susceptibility of viruses carrying K156N, 3'PPT mutations, or both were measured. Viral evolution was assessed in cell culture. RESULTS: Structural models indicated that K156N altered viral DNA binding. K156N reduced strand transfer activity through decreased affinity for the LTR but increased 3'-processing. The K156N virus had normal infectivity, whereas the 3'PPT mutations decreased infectiousness sixfold and lowered maximal infectivity. K156N partially compensated for this defect, but maximal infectivity remained diminished. K156N also partially compensated for defects in replicative capacity imposed by 3'PPT mutations. K156N alone did not confer resistance against dolutegravir, nor did it increase the modest (2.5-fold) resistance conferred by the 3'PPT mutations. K156N alone promoted the spontaneous emergence of 3'PPT mutations distinct from those seen in DOMONO. CONCLUSIONS: These findings establish a direct functional relationship between natural variation in HIV-1 integrase and the emergence of 3'PPT mutations. People harbouring a virus with the K156N natural polymorphism may be predisposed to developing 3'PPT mutations upon failure with DTG. However, the clinical relevance of this association remains to be established.
引用
- van Osch JAT, Voermans JJC, Ouzerne H, et al. Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure. J Antimicrob Chemother. 2026. PMID: 41636646. doi:10.1093/jac/dkag033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。